Please assess the completion status of the following clinical trial:

Trial Title: Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be \>18 years of age~2. Histologic diagnosis of AL amyloidosis~3. Genetic testing must be negative for transthyretin mutations~4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2~5. Patients should have received at least one line with an alkylating agent and/or a proteasome inhibitor and dexamethasone and not be in VGPR or CR at the time of inclusion~6. Measurable hematologic disease:~7. Symptomatic organ involvement~8. Wash-out period of at least 4 weeks from previous antitumor therapy or any investigational treatment or 5 half-lives from previous antibodies, whichever is longer,~9. Adequate bone marrow function prior to 1st drug intake~10. Adequate organ function defined as:~11. Women with childbearing potential must be practicing one of the effective methods of birth control~12. A man who has not had a vasectomy and who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control~13. Only patients who are informed of the investigational nature of this study and sign and give written informed consent~Exclusion Criteria:~1. Amyloid-specific syndrome, such as carpal tunnel syndrome or skin purpura as the only evidence of disease. The finding of isolated vascular amyloid in a bone marrow biopsy specimen or in a plasmacytoma is not indicative of systemic amyloidosis~2. Isolated soft tissue involvement~3. Presence of non-AL amyloidosis~4. Bone marrow plasma cells \>30% on bone marrow aspirate at screening~5. Cardiac mayo stage IIIb disease.~6. Repetitive ventricular arrhythmias on 24h Holter ECG despite anti-arrhythmic treatment, except if a pacemaker has been implanted.~7. Chronic atrial fibrillation~8. Supine systolic blood pressure \<100 mmHg~9. Subject is a woman who is pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 3 months after the last dose of any component of the treatment regimen. Or, subject is a man who plans to father a child while enrolled in this study or within 3 months after the last dose of any component of the treatment regimen~10. Clinically overt multiple myeloma with lytic bone lesions~11. Patients with uncontrolled infection or active malignancy~12. Any uncontrolled or severe cardiovascular or pulmonary disease~13. Subjects with psychiatric illnesses or social situations that would preclude them understanding the informed consent, study compliance or the ability to tolerate study procedures and/or study therapy~14. Subjects with known chronic obstructive pulmonary disease (COPD)~15. Subject has known moderate or severe persistent asthma within the past 2 years~16. Previous anti-CD38 therapy~17. Hypersensitivity to Dexamethasone that would prohibit treatment with study therapy~18. Known positive for HIV or active hepatitis B or C~19. Refusal to consent or protected by legal regime

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daratumumab (Type: EXPERIMENTAL): Patient will receive Daratumumab every week for the first 2 cycles then every 2 weeks from cycle 3 through cycle 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete